Mexidol
Phase 3Small molecule
Mexidol is one of 89 small molecule programs targeting Cerebral ischemia. It is currently in Phase 3.
4
Indications
7
Total Trials
0
Active Trials
88
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Mexidol
PPharmasoft
Phase 3
Activase
RochePreclinical
Folvite
Eli LillyPreclinical
Proamatine
TakedaPreclinical
Repatha
AmgenPreclinical
Pradaxa
Boehringer IngelheimPreclinical
Botox
RRevance Therapeutics, Inc.
Preclinical
Periactin
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Zantac 150
CChattem
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Open-Angle Glaucoma2 trials
Rehabilitation1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mexidol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- PPharmasoft